-
1.发明授权Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers 失效具有含有聚氧化烯共聚物的热可逆凝胶的体腔药物递送
公开(公告)号：US5292516A
公开(公告)日：1994-03-08
申请号：US790664
申请日：1991-11-08
CPC分类号： A61K47/10 , A61K47/18 , A61K9/0014 , Y10S514/944
摘要： Isotonic, iso-osmotic, pH balanced thermoreversible gels are ideal vehicles for drug delivery to a body cavity of a mammal. The osmolality in the gel state can be calculated by assuming that a polyoxyalkylene block copolymer or polyether present in said gel does not contribute to the osmolality in the gel state, although it does contribute to the osmolality in the liquid state.
摘要翻译： 等渗，等渗，pH平衡的热可逆性凝胶是药物输送到哺乳动物体腔的理想载体。 可以通过假设存在于所述凝胶中的聚氧化烯嵌段共聚物或聚醚在凝胶状态下不影响重量摩尔渗透压浓度来计算凝胶状态下的重量摩尔渗透压浓度，尽管它确实有助于液态渗透压。
-
2.发明授权Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers 失效通过注射含有聚氧化烯共聚物的热可逆凝胶进行药物递送
公开(公告)号：US5306501A
公开(公告)日：1994-04-26
申请号：US791119
申请日：1991-11-08
CPC分类号： A61K47/18 , A61K47/10 , A61K9/0019 , Y10S514/944
摘要： Isotonic, iso-osmotic, pH balanced thermoreversible gels are ideal medical devices or vehicles for drug injection into the body of a mammal. The osmolality in the gel state can be calculated by assuming that a polyoxyalkylene block copolymer or polyether present in said gel does not contribute to the osmolality in the gel state, although it does contribute to the osmolality in the liquid state.
摘要翻译： 等渗，等渗，pH平衡的热可逆凝胶是用于药物注射到哺乳动物体内的理想医疗装置或载体。 可以通过假设存在于所述凝胶中的聚氧化烯嵌段共聚物或聚醚在凝胶状态下不影响重量摩尔渗透压浓度来计算凝胶状态下的重量摩尔渗透压浓度，尽管它确实有助于液态渗透压。
-
3.发明授权Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality 失效用聚氧亚烷基聚合物热可逆凝胶的局部药物递送可调节pH和重量摩尔渗透压浓度
公开(公告)号：US5298260A
公开(公告)日：1994-03-29
申请号：US895949
申请日：1992-06-09
CPC分类号： A61K9/0014 , A61K47/10 , A61K47/18 , Y10S514/944
摘要： Iso-osmotic, hyperosmotic, or hypo-osmotic, pH balanced, thermoreversible gels are ideal medical devices or vehicles for drug delivery to the skin of a mammal. The osmolality in the gel state can be calculated by assuming that a polyoxyalkylene block copolymer or polyether present in said gel does not contribute to the osmolality in the gel state, although it does contribute to the measured osmolality in the liquid state.
摘要翻译： 等渗，高渗或低渗，pH平衡的热可逆性凝胶是药物递送至哺乳动物皮肤的理想医疗装置或载体。 可以通过假定存在于所述凝胶中的聚氧化烯嵌段共聚物或聚醚对凝胶状态中的重量摩尔渗透压浓度没有贡献来计算凝胶状态下的重量摩尔渗透压浓度，尽管它确实有助于在液态中测量的重量摩尔渗透压浓度。
-
4.发明授权Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH 失效使用热可逆性聚氧化烯凝胶进行眼科药物输送可调节pH值
公开(公告)号：US5300295A
公开(公告)日：1994-04-05
申请号：US759234
申请日：1991-09-13
CPC分类号： A61K47/10 , A61K47/18 , A61K9/0048 , A61K9/06 , Y10S514/912 , Y10S514/944
摘要： Aqueous gel drug delivery compositions and medical devices, useful for treating an eye condition, having hyperosmotic, iso-osmotic or hypo-osmotic characteristics in the gel state, are obtained by calculating the osmolality required in the liquid state to reach a desired osmotic force in the gelled state by assuming that a polyoxyalkylene block copolymer does not contribute to the osmolality in the gel state.
摘要翻译： 通过计算在液体状态下达到期望的渗透压所需的重量摩尔渗透压浓度，可以获得在凝胶状态下具有高渗透性，渗透性或低渗透性的治疗眼睛状况的水凝胶药物递送组合物和医疗装置 通过假定聚氧化烯嵌段共聚物在凝胶状态下不影响重量摩尔渗透压浓度，则凝胶化状态。
-
公开(公告)号：US4976683A
公开(公告)日：1990-12-11
申请号：US220779
申请日：1988-07-18
IPC分类号： A61M1/28
摘要： This invention relates to an improved method for conducting peritoneal dialysis with a decreased total volume of dialysis fluid used and increased efficacy parameters such as ultrafiltration rate, urea clearance rate and dialysate volume as compared to conventional techniques. In the method of this invention, a fluid communication through the peritoneal membrane into the peritoneal cavity of a patient in need of peritoneal dialysis treatment is established. An initial volume of an aqueous peritoneal dialysis composition containing an osmotic agent is instilled into the peritoneal cavity through the fluid communication. The dialysis composition contains an amount of dissolved osmotic agent (i) that is insufficient to adequately dialyze the patient during a predetermined time period of dialysis treatment, but (ii) that is present at an osmolarity that is greater than the osmolarity of the body fluids in contact with the membrane, such that an osmolarity gradient is created across the membrane between the composition and the body fluids. A flux of water and solute enters the composition from the body fluids by means of that gradient.A further amount of dissolved osmotic agent is released into the instilled dialysis composition to form a modified dialysis composition. That further osmotic agent is released in an amount sufficient to maintain a substantially constant osmolarity gradient between the modified dialysis composition and the body fluids such that the water and solute flux continues to enter into the modified dialysis composition during the predetermined dialysis time period. The modified dialysis composition is substantially removed from the peritoneal cavity at the end of the treatment time period.
摘要翻译： 本发明涉及一种改进的腹膜透析方法，与常规技术相比，使用的透析液的总体积减少，并且提高了功效参数，例如超滤速率，尿素清除率和透析液体积。 在本发明的方法中，建立了通过腹膜进入需要腹膜透析治疗的患者的腹腔的液体连通。 通过流体连通将含有渗透剂的含水性腹膜透析组合物的初始体积滴入腹膜腔。 透析组合物含有一定量的溶解渗透剂（i），其不足以在透析治疗的预定时间段期间充分透析患者，但（ii）存在的渗透压大于体液的渗透压 与膜接触，使得跨组合物和体液之间的膜产生渗透压梯度。 水和溶质的通量通过该梯度从体液进入组合物。 将另外量的溶解的渗透剂释放到滴入浓缩组合物中以形成改性透析组合物。 该释放出的进一步的渗透剂量足以在修饰的透析组合物和体液之间保持基本恒定的渗透压梯度，使得水和溶质通量在预定的透析时间期间继续进入修饰的透析组合物。 在治疗时间段结束时，改良的透析组合物基本上从腹膜腔中除去。
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
